Latest news about Coral Laboratories
Coral Laboratories
458.70
+4.10(+0.90%)
Company Performance:
View Company Insights1D+0.90%
1M+14.08%
6M-8.18%
1Y-33.83%
5Y+13.89%
More news about Coral Laboratories
24Mar 26
Coral Laboratories Completes Capacity Expansion at Dehradun Plant, Commences Commercial Operations
Coral Laboratories Ltd successfully completed capacity expansion of its General Pharmaceuticals Formulation (Ointment) unit at Dehradun plant to 360,000 kgs capacity. The company commenced commercial operations at the expanded facility, following the initial announcement made on October 13, 2025. This expansion enhances the company's manufacturing capabilities in pharmaceutical formulations.
13Feb 26
Coral Laboratories Q3FY26 Results: Net Profit Declines 54.84% to ₹277.55 Lakhs
Coral Laboratories Limited reported challenging Q3FY26 results with net profit declining 54.84% to ₹277.55 lakhs and revenue dropping 6.19% to ₹2156.42 lakhs compared to the same quarter last year. The nine-month performance was even weaker, with net profit falling 47.70% to ₹1115.74 lakhs and revenue declining 31.60% to ₹5942.04 lakhs. Higher material costs and increased operational expenses contributed to the margin pressure, while earnings per share dropped to ₹7.77 from ₹17.20 in Q3FY25.
30Dec 25
Coral Laboratories Company Secretary and Compliance Officer Resigns Effective January 31, 2026
Coral Laboratories has announced the resignation of Mrs. Dhwani Desai from her position as Company Secretary and Compliance Officer, effective January 31, 2026. She is stepping down to pursue another career opportunity, and the Board has accepted her resignation. Following her departure, Mrs. Desai will also cease to be Key Managerial Personnel of the company. The pharmaceutical company has complied with SEBI disclosure requirements by informing BSE Limited of this personnel change.
13Oct 25
Coral Laboratories Approves ₹30 Crore Capacity Expansion at Dehradun Plant
Coral Laboratories Limited has approved a capacity expansion project at its Dehradun plant, aiming to triple ointment manufacturing capacity from 180,000 kgs to 540,000 kgs. The ₹30 crore investment, to be financed through bank overdraft and internal accruals, is expected to complete in 6 months. The expansion addresses growing demand in domestic and international markets, with current capacity utilization at 80%. The company aims to meet captive demand, support sales growth, and facilitate overall business expansion.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,863.20
(+2.10%)
6,921.50
(+1.85%)
4,403.90
(+2.52%)
1,436.70
(+8.22%)
1,303.60
(+3.03%)
2,258.20
(+1.92%)
2,462.20
(+2.27%)
991.70
(+5.58%)
1,510.90
(+0.89%)
1,315.50
(+2.73%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
